Company Overview of Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. is a clinical-stage pharmaceutical company that focuses on the development of product candidates for cystic fibrosis. It develops a portfolio of small molecule inhibitors of S-nitrosoglutathione, which have been shown to preserve endogenous GSNO and produce potent effects on CFTR modulation and inflammation in experimental models. Nivalis Therapeutics, Inc. was formerly known as N30 Pharmaceuticals, Inc. and changed its name to Nivalis Therapeutics, Inc. in February 2015. The company was founded in 2007 and is based in Boulder, Colorado.
3122 Sterling Circle
Boulder, CO 80301
Founded in 2007
Key Executives for Nivalis Therapeutics, Inc.
Chief Executive Officer, President and Director
Executive Vice President of Product Development & Regulatory
Vice President of Research
Compensation as of Fiscal Year 2014.
Nivalis Therapeutics, Inc. Key Developments
N30 Pharmaceuticals, Inc. has Changed its Name to Nivalis Therapeutics, Inc
Feb 24 15
N30 Pharmaceuticals, Inc. changed its name to Nivalis Therapeutics, Inc.
N30 Pharmaceuticals Appoints R. Michael Carruthers as Chief Financial Officer
Feb 3 15
N30 Pharmaceuticals, Inc. announced that R. Michael Carruthers has been appointed to the position of chief financial officer (CFO). Mr. Carruthers brings more than 25 years of executive-level financial expertise to N30 Pharma. Most recently, Mr. Carruthers served on Array BioPharma Inc.'s executive team as the CFO, where he executed the company's initial public offering and multiple follow-on equity and debt fund raises. Mr. Carruthers is also experienced in strategic planning and managing organizations through rapid growth, and with transactions and negotiations involving partnering, licensing, drug discovery and clinical development. Prior to joining Array, Mr. Carruthers served as CFO of Sievers Instrument, Inc., and before joining Sievers was the treasurer and controller for the Waukesha division of Dover Corporation. Mr. Carruthers was previously employed as an accountant with Coopers & Lybrand, LLP. Mr. Carruthers received a B.S. in accounting from the University of Colorado and a M.B.A. from the University of Chicago.
N30 Pharmaceuticals, Inc. Appoints Jon Congleton as Director, President and CEO
Dec 22 14
N30 Pharmaceuticals, Inc. announced that the company's board of directors has appointed Jon Congleton to the position of President and Chief Executive Officer. Congleton will also join the company's board of directors. Congleton brings more than twenty-five years of senior management and product commercialization experience in the pharmaceutical industry to N30 Pharma. Congleton was previously at Teva Pharmaceuticals Ltd., where over 18 years he held positions in general management and global strategic marketing, including Senior Vice President of Teva's Central Nervous System Global Franchise, Senior Vice President of the Global Medicines Group, and General Manager of Teva Neuroscience, Inc.
Similar Private Companies By Industry
Recent Private Companies Transactions
November 18, 2014